Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed FL.~* Documented CD20+ FL.~* Relapsed or refractory to any prior rituximab-containing regimen.~* Previously treated with a maximum of 4 cancer-directed treatment regimens.~* At least 1 measurable lesion \> 1.5 cm in at least 1 dimension by computed tomography or magnetic resonance imaging.~* Must be willing to undergo an incisional or excisional lymph node biopsy of accessible adenopathy or provide the most recent, available archived tumor biopsy.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.~Exclusion Criteria:~* Clinical evidence of transformation to a more aggressive subtype of lymphoma or Grade 3B FL.~* History of central nervous system lymphoma (either primary or metastatic).~* Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host disease following allogeneic transplant or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug administration.~* Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug.~* Prior treatment with a selective PI3Kδ inhibitor or a pan PI3K inhibitor.~* Prior treatment with bendamustine (within 12 months of the start of study treatment). Subjects with prior bendamustine treatment (\> 12 months before the start of study treatment) are eligible if they meet the following criteria:~  * Did not discontinue because of tolerability concerns.~ * Achieved either partial or CR to the bendamustine regimen of at least 12 months in duration before relapse/progression.~ * Experienced progression following a regimen containing an alkylating agent.~* Received prior obinutuzumab.~* Received rituximab within 4 weeks of study start.~* Prior treatment-related toxicities that have not resolved to ≤ Grade 1 before the date of study drug administration except for stable chronic toxicities (≤ Grade 2) not expected to resolve (eg, stable Grade 2 peripheral neurotoxicity).~* Received any prior monoclonal antibody (except an anti-CD20 antibody) within 90 days before the date of study start.~* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (eg, subjects in whom re-administration with rituximab would be contraindicated for safety reasons).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parsaclisib + Hexal and Gazyvaro (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).